Navigation Links
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:2/10/2011

SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Optimer. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. is acting as the sole book-running manager for the proposed offering and Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC are acting as co-managers for the proposed offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Optimer Pharmaceuticals, Inc.Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the proposed public offering of securities by Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to market conditions and the satisfaction of customary closing conditions, and other risks detailed in Optimer's filings with the SEC.  All forward-looking statements are qualified in their entirety by this cautionary statement, and Optimer undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
2. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
3. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
4. Optimer Pharmaceuticals Announces Key Additions to Management Team
5. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
6. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 The fast-growing ... the United States . According to the 2017 ... industry is expected to create 283,422 jobs by 2020, with ... over the next four years. The accelerating pace of cannabis ... growth of legal cannabis market, which will further create more ...
(Date:2/23/2017)... SEOUL, South Korea , Feb. 23, 2017 LG ... 70mw UV-C LED for sterilization applications. As its sterilization performance is ... LED produces the short wavelength ultraviolet rays in the range of ... prevents the proliferation of bacteria by destroying their DNA. LG Innotek,s ... ...
(Date:2/23/2017)... ML Capital Group, Inc. (USOTC: MLCG) today announced acquiring ... , a Colorado -based cannabis tourism company. MLCG ... PURA) to enter Colorado,s $19 billion tourism ... acquisition announced today is intended to accelerate MLCG,s Colorado ... ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Top cosmetic and ... Patriot program today with a new Indiegogo campaign . Individuals are now ... veterans in the Los Angeles area, either as a participating patient or through an ...
(Date:2/23/2017)... FALLS CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... , worries, or problems. He has also continued to spiritually evolve, which is the ... his published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... ... 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches ... The Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and ... D’ traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail ...
Breaking Medicine News(10 mins):